In 607 adults with virologically suppressed HIV-1, switching to once-weekly oral islatravir-lenacapavir was noninferior to continuing daily B/F/TAF: HIV-1 RNA ≥50 copies/mL at week 48 in 0% vs 0.3% (difference −0.3 points). Serious adverse events: 5.3% vs 4.6%.
RCTn = 607
Rockstroh et al. Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment